Abstract
Purpose
The World Health Organization revised its human papillomavirus (HPV) vaccination recommendations to include a two (2-) dose schedule for girls aged ≤ 15 years. We investigated acceptability of 2- versus 3-dose schedule among adolescent vaccination providers and mothers of adolescent girls in five countries.
Methods
Adolescent vaccination providers (N = 151) and mothers of adolescent girls aged 9–14 years (N = 118) were recruited from Argentina, Malaysia, South Africa, South Korea, and Spain. We assessed providers’ preference for a 2- versus 3-dose HPV vaccination schedule via quantitative surveys. Mothers’ attitudes towards a 2-dose schedule were assessed through focus group discussions.
Results
Most adolescent providers preferred a 2- over a 3-dose HPV vaccination schedule (overall: 74%), with preference ranging from 45.2% (South Africa) to 90.0% (South Korea). Lower cost, fewer clinic visits, and higher series completion were commonly cited reasons for 2-dose preference among providers and mothers. Safety and efficacy concerns were commonly cited barriers to accepting a 2-dose HPV vaccination schedule among providers and mothers. Mothers generally accepted the reduced schedule, however requested further information from a trusted source.
Conclusions
Adolescent vaccination providers and mothers preferred the 2-dose over 3-dose HPV vaccination schedule. Acceptability of a 2-dose HPV vaccination could be improved with additional information to providers and mothers on HPV vaccination safety and efficacy.
Similar content being viewed by others
Abbreviations
- HIV:
-
Human immunodeficiency virus
- HPV:
-
Human papillomavirus
- LMIC:
-
Low- and middle-income country
- SAGE:
-
Strategic Advisory Group of Experts
- STI:
-
Sexually transmitted infections
- WHO:
-
World Health Organization
References
World Health Organization (2014) Human papillomavirus vaccines: WHO position paper. World Health Organization, Geneva
World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017. World Health Organization, Geneva
Clendinen C, Zhang Y, Warburton R, Light D (2016) Manufacturing costs of HPV vaccines for developing countries. Vaccine 34(48):5984–5989
Remes P, Selestine V, Changalucha J, Ross D, Wight D, de Saniose S, Hayes R, Watson-Jones D (2012) A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 30(36):5363–5367
LaMontagne D, Barge S, Le N, Mugisha E, Penny M, Gandhi S, Janmohamed A, Kumakech E, Mosqueira N, Nguyen N, Paul P, Tang Y, Minh T, Uttekar B, Jumaan A (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 89(11):821–830B
Brewer N, Fazekas K (2007) Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45(2–3):107–114
Wigle JCE, Watson-Jones D (2013) Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMIC): health system experiences and prospects. Vaccine 31(37):3811–3817
Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M (2014) Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32(6):725–732
Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele D, Kollmann T, Halperin S, Langley J, Bettinger J, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802
Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccine 7(12):1374–1386
Romanowski B, Schwarz T, Ferguson M, Klaus P, Dionne M, Schulze K, Ramjattan B, Hillemanss P, Behre U, Suryakiran P, Thomas F, Struyf F (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Hum Vaccines Immunother 10(5):1155–1165
Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Behre U, Hillemanns P, Suryakiran P, Thomas F, Struyf F (2016) Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Vaccine 12(1):20–29
World Health Organization (2017) Immunization, vaccines and biologicals: human papillomavirus (HPV). http://www.who.int/immunization/hpv/en/. Accessed July 2018
Francis S, Katz M (2013) The HPV vaccine: a comparison of focus groups conducted in South Africa and Ohio Appalachia. Matern Child Health J 17(7):1222–1229
Hertweck S, LaJoie A, Pinto M, Flamini L, Lynch T, Logsdon M (2013) Health care decision making by mothers for their adolescent daughters regarding the quadrivalent HPV vaccine. J Pediatr Adolesc Gynecol 26(2):96–101
Katz I, Nkala B, Dietrich J, Wallace M, Bekker L, Pollenz K, Bogart L, Wright A, Tsai A, Bangsberg D, Gray G (2013) A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS ONE 8(8):e72094
Rambout L, Tashkandi M, Hopkins L, Tricco A (2014) Self-reported barriers and facilitators to preventive human papillomavirus vaccination among adolescent girls and young women: a systematic review. Prev Med 58:22–32
Oh J, Lim M, Yun E, Lee E, Shin H (2010) Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 28(7):1854–1860
Navarro-Illana P, Caballero P, Tuells J, Puig-Barbera J, Diez-Domingo J (2015) Acceptability of human papillomavirus vaccine in mothers from Valencia (Spain). An Pediatr 83(5):318–327
Watson-Jones D, Mugo N, Lee S, Mathai M, Vusha S, Ndirangu G, Ross D (2015) Access and attitudes of HPV vaccination amongst hard-to-reach populations in Jenya. PLoS ONE 10(6):e0123701
Crann S, Barata P, Mitchell R, Mawhinney LT, Chirenje P, Stewart M D (2016) Healthcare providers’ perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe. J Psychosom Obstet Gynecol 37(4):147–155
Hopkins T, Wood N (2013) Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 31(13):1673–1679
Asiedu G, Breitkopf C, Kremers W, Ngo Q, Nguyen N, Barenberg B, Tran V, Dinh T (2015) Vietnamese health care providers’ preferences regarding recommendation of HPV vaccines. Asian Pac J Cancer Prev 16(12):4895–4900
Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S (2014) Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 168(1):76–82. https://doi.org/10.1001/jamapediatrics.2013.2752
McLellan E, MacQueen KM, Neidig JL (2003) Beyond the qualitative interview: data preparation and transcription. Field Methods 15(1):63–84
Vaismoradi M, Turunen H, Bondas T (2013) Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci 15(4):398–405
MacQueen KM, McLellan-Lemal E, Bartholow K, Milstein B (2008) Team-based codebook development: structure, process and agreement. In: Handbook for team-based qualitative research. Altamina Press, Lanham, pp 119–135
Bernard HR, Ryan GW (2010) Analyzing qualitative data: systematic approaches. Sage, Thousand Oaks
Guest G, MacQueen KM, Namey EE (2012) applied thematic analysis. Sage, Thousand Oaks
Saldana J (2013) The coding manual for qualitative researchers, 3rd edn. Sage, Thousand Oaks
Jit M, Brisson M, Laprise J, Hong Choi Y (2015) Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 350
Laprise J, Markowitz L, Chesson H, Drolet M, Brisson M (2016) Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 214(5):685–688
Laprise J-F, Markowitz LE, Chesson HW, Drolet M, Brisson M (2016) Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. J Infect Dis 214(5):685–688
Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT (2016) Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine 34(9):1187–1192. https://doi.org/10.1016/j.vaccine.2016.01.023
Smith P, Stokley S, Bednarczyk R, Orenstein W, Omer S (2016) HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine 18(34):1604–1610
Rahman M, Laz T, McGrath C, Berenson A (2016) Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old U.S. adolescent children. Clin Pediatr 54(4):371–375
Allison MA, Hurley LP, Marokwitz L, Crane LA, Brtnikova M, Beaty BL, Snow M, Cory J, Stokley S, Roark J, Kempe A (2016) Primary care physicians’ perspectives about HPV vaccine. Pediatrics 137(2):e20152488
Kulczycki A, Qu H, Shewchuk R (2016) Primary care physicians’ adherence to guidelines and their likelihood to prescribe the human papillomavirus vaccine for 11- and 12-year-old girls. Women’s Health Issues 26(1):34–39
Kyong-No N, Chang K, Cho S, Park S, Park S (2017) Attitudes regarding HPV vaccinations of children among mothers with adolescent daughters in Korea. J Korean Med Sci 32(1):130–134
Vermandere H, Naanyu V, Mabeya H, Broeck D, Michielsen K, Degomme O (2014) Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS ONE 10(3):e0117761
Cunningham M, Skrastins E, Fitzpatrick R, Jindal P, Olola O, Yeates K, Booth C, Carpenter J, Aronson K (2015) Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open 5(3):e005828
Jaspers L, Budiningsih S, Wolterbeek R, Henderson F, Peters A (2011) Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: a cross-sectional study. Vaccine 29(44):7785–7793
Cover J, Nghi N, LaMontagne D, Huyen D, Hien N, Nga le T (2012) Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health 12(629):629
Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P (2014) Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine 32(19):2150–2159
Gallagher KE, Howard N, Kabakama S, Mounier-Jack S, Griffiths UK, Feletto M, Burchett HED, LaMontagne DS, Watson-Jones D (2017) Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. PLoS One. https://doi.org/10.1371/journal.pone.0177773
Ferrer H, Trotter C, Hickman M, Audrey S (2014) Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health 14:700
Galagan S, Paul P, Menezes L, LaMontagne D (2013) Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine 31(30):3072–3078
Widman C, Rodriguez E, Saad-Harfouche F, Tawrozek A, Erwin D, Mahoney M (2017) Clinician and parent perspectives on educational needs for increasing adolescent HPV vaccination. J Cancer Educ 33:332–339
Acknowledgments
The authors gratefully acknowledge the participants of this study. The authors thank Suzanne Landi, Shoshana Goldberg, and Sara Smith for their assistance in developing this manuscript. JYI was supported by a NIH NRSA individual predoctoral fellowship (F31-CA210474-01A1). Cervarix is a trademark owned by or licensed to the GSK group of companies.
Funding
This study was funded by GlaxoSmithKline Biologicals SA (Study ID: 117339); all data collection, analysis, and interpretation was conducted by study co-authors, and GSK had the opportunity to review this paper. GSK did not have input into the research data collection, analysis, or interpretation of results.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Jennifer S. Smith has received research grants, served on paid advisory boards, and/or been a paid speaker for GSK group of companies and Merck & Co., Inc. over the past 5 years. The remaining authors have no conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Islam, J.Y., Hoyt, A.M., Ramos, S. et al. Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries. Cancer Causes Control 29, 1115–1130 (2018). https://doi.org/10.1007/s10552-018-1085-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-018-1085-1